Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 4 (2007), Issue 2 (February)

1. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
   Oncogene, 26(5): 662-72. [Abstract] [Full-text]
2. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning.
   FASEB J, 21(2): 618-28. [Abstract] [Full-text]
3. Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease.
   Curr Opin Gastroenterol, 23(2): 149-58. [Abstract] [Full-text]
4. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands.
   Oral Oncol, 43(1): 33-6. [Abstract] [Full-text]
5. Small cell lung cancer and targeted therapies.
   Curr Opin Oncol, 19(2): 103-8. [Abstract] [Full-text]
6. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment.
   Cancer Res, 67(3): 1113-20. [Abstract] [Full-text]
7. Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells.
   Cancer Res, 67(3): 851-3. [Abstract] [Full-text]
8. Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.
   Blood, 109(4): 1701-11. [Abstract] [Full-text]
9. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
   Blood, 109(4): 1408-13. [Abstract] [Full-text]
10. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.
    Blood, 109(4): 1782-9. [Abstract] [Full-text]
11. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.
    Blood, 109(4): 1643-52. [Abstract] [Full-text]
12. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.
    Leuk Res, 31(4): 563-7. [Abstract] [Full-text]
13. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice.
    Res Vet Sci, 82(2): 239-41. [Abstract] [Full-text]
14. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
    Semin Hematol, 44(1): 25-31. [Abstract] [Full-text]
15. Resistance to targeted therapy in chronic myelogenous leukemia.
    Semin Hematol, 44(1): 15-24. [Abstract] [Full-text]
16. The biology of chronic myelogenous leukemia: implications for imatinib therapy.
    Semin Hematol, 44(1): 4-14. [Abstract] [Full-text]
17. Changes in expression of apoptosis-related genes are linked to the molecular response to imatinib treatment in chronic-phase chronic myeloid leukemia patients.
    Acta Haematol, 117(2): 83-90. [Abstract] [Full-text]
18. Megakaryocytic blast crisis as first presentation of chronic myeloid leukemia.
    Am J Hematol, 82(3): 231-3. [Abstract] [Full-text]
19. PDGFR-alpha as a potential therapeutic target in uterine sarcomas.
    Gynecol Oncol, 104(3): 524-8. [Abstract] [Full-text]
20. In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures.
    Biopolymers, 85(4): 333-48. [Abstract] [Full-text]
21. Novel compounds with antiproliferative activity against imatinib-resistant cell lines.
    Mol Cancer Ther, 6(2): 655-66. [Abstract] [Full-text]
22. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
    Mol Cancer Ther, 6(2): 773-81. [Abstract] [Full-text]
23. Why should we still care about oncogenes?
    Mol Cancer Ther, 6(2): 418-27. [Abstract] [Full-text]
24. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec).
    Nucl Med Biol, 34(2): 153-63. [Abstract] [Full-text]
25. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
    Cancer Res, 67(4): 1680-8. [Abstract] [Full-text]
26. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients.
    J Eur Acad Dermatol Venereol, 21(3): 384-7. [Abstract] [Full-text]
27. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.
    Blood, 109(5): 2147-55. [Abstract] [Full-text]
28. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.
    Blood, 109(5): 2112-20. [Abstract] [Full-text]
29. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
    Leukemia, 21(3): 421-6. [Abstract] [Full-text]
30. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.
    Leukemia, 21(3): 489-93. [Abstract] [Full-text]
31. An ant algorithm for the conformational analysis of flexible molecules.
    J Comput Chem, 28(5): 890-8. [Abstract] [Full-text]
32. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
    Leukemia, 21(3): 397-402. [Abstract] [Full-text]
33. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.
    Oncogene, 26(8): 1188-200. [Abstract] [Full-text]
34. Important therapeutic targets in chronic myelogenous leukemia.
    Clin Cancer Res, 13(4): 1089-97. [Abstract] [Full-text]
35. Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.
    Int J Hematol, 85(2): 132-9. [Abstract] [Full-text]
36. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
    Leuk Lymphoma, 48(2): 295-301. [Abstract] [Full-text]
37. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
    Leuk Lymphoma, 48(2): 283-9. [Abstract] [Full-text]
38. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
    Cancer, 109(5): 899-906. [Abstract] [Full-text]
39. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
    Cancer, 109(5): 907-14. [Abstract] [Full-text]
40. Sunitinib: from rational design to clinical efficacy.
    J Clin Oncol, 25(7): 884-96. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.